Literature DB >> 32655143

Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia.

Emily Gruber1,2, Rheana L Franich1, Jake Shortt1,3,4, Ricky W Johnstone1,2, Lev M Kats5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32655143     DOI： 10.1038/s41375-020-0973-z

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  5 in total

Review 1.  The contributing factors of resistance or sensitivity to epigenetic drugs in the treatment of AML.

Authors:  Shohre Karimi Kelaye; Fatemeh Najafi; Bahareh Kazemi; Zahra Foruzandeh; Farhad Seif; Saeed Solali; Mohammad-Reza Alivand
Journal:  Clin Transl Oncol       Date:  2022-01-25       Impact factor: 3.405

2.  Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients.

Authors:  Pavla Koralkova; Monika Belickova; David Kundrat; Michaela Dostalova Merkerova; Zdenek Krejcik; Katarina Szikszai; Monika Kaisrlikova; Jitka Vesela; Pavla Vyhlidalova; Jan Stetka; Alzbeta Hlavackova; Jiri Suttnar; Patrik Flodr; Jan Stritesky; Anna Jonasova; Jaroslav Cermak; Vladimir Divoky
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

Review 3.  Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.

Authors:  Julia Stomper; John Charles Rotondo; Gabriele Greve; Michael Lübbert
Journal:  Leukemia       Date:  2021-05-06       Impact factor: 11.528

4.  Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy.

Authors:  Ratnakar Singh; Zeeshan Fazal; Emmanuel Bikorimana; Raya I Boyd; Cliff Yerby; Megan Tomlin; Hannah Baldwin; Doha Shokry; Andrea K Corbet; Khadeeja Shahid; Aleyah Hattab; Sarah J Freemantle; Michael J Spinella
Journal:  Mol Oncol       Date:  2021-09-15       Impact factor: 6.603

5.  Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT.

Authors:  Kavita Raj; Dirk-Jan Eikema; Vipul Sheth; Linda Koster; Liesbeth C de Wreede; Didier Blaise; Carmela Di Grazia; Yener Koc; Victoria Potter; Patrice Chevallier; Lucia Lopez-Corral; Depei Wu; Stephan Mielke; Johan Maertens; Ellen Meijer; Anne Huynh; Jakob Passweg; Thomas Luft; Jose Antonio Pérez-Simón; Fabio Ciceri; Agnieszka Piekarska; G Hayri Ozsan; Nicolaus Kröger; Marie Robin; Ibrahim Yakoub-Agha
Journal:  Blood Cancer J       Date:  2022-09-28       Impact factor: 9.812
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.